Cell-based therapies for the preterm infant

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

The severely preterm infant receives a multitude of life-saving interventions, many of which carry risks of serious side effects. Cell therapy is an important and promising arm of regenerative medicine that may address a number of these problems. Most forms of cellular therapy use stem/progenitor cells or stem-like cells, which have the capacity to migrate, engraft and exert anti-inflammatory effects. Although some of these cell-based therapies have made their way to clinical trials in adults, little headway has been made in the neonatal patient group. This review discusses the efficacy of cell therapy in preclinical studies to date and their potential applications to diseases that afflict many prematurely born infants. Specifically, we identify the major hurdles that must be overcome before cell therapies can be safely used in the neonatal intensive care unit.
Original languageEnglish
Pages (from-to)1614-1628
Number of pages15
JournalCytotherapy
Volume16
Issue number12
DOIs
Publication statusPublished - 1 Dec 2014

Keywords

  • bronchopulmonary dysplasia
  • cell therapy
  • human amnion epithelial cells
  • mesenchymal stromal cells
  • prematurity

Cite this

@article{e9c0002795644365bd817e2f281b812f,
title = "Cell-based therapies for the preterm infant",
abstract = "The severely preterm infant receives a multitude of life-saving interventions, many of which carry risks of serious side effects. Cell therapy is an important and promising arm of regenerative medicine that may address a number of these problems. Most forms of cellular therapy use stem/progenitor cells or stem-like cells, which have the capacity to migrate, engraft and exert anti-inflammatory effects. Although some of these cell-based therapies have made their way to clinical trials in adults, little headway has been made in the neonatal patient group. This review discusses the efficacy of cell therapy in preclinical studies to date and their potential applications to diseases that afflict many prematurely born infants. Specifically, we identify the major hurdles that must be overcome before cell therapies can be safely used in the neonatal intensive care unit.",
keywords = "bronchopulmonary dysplasia, cell therapy, human amnion epithelial cells, mesenchymal stromal cells, prematurity",
author = "Dandan Zhu and Wallace, {Euan Morrison} and Lim, {Rebecca Seok Wai}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.jcyt.2014.06.004",
language = "English",
volume = "16",
pages = "1614--1628",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Elsevier",
number = "12",

}

Cell-based therapies for the preterm infant. / Zhu, Dandan; Wallace, Euan Morrison; Lim, Rebecca Seok Wai.

In: Cytotherapy, Vol. 16, No. 12, 01.12.2014, p. 1614-1628.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cell-based therapies for the preterm infant

AU - Zhu, Dandan

AU - Wallace, Euan Morrison

AU - Lim, Rebecca Seok Wai

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The severely preterm infant receives a multitude of life-saving interventions, many of which carry risks of serious side effects. Cell therapy is an important and promising arm of regenerative medicine that may address a number of these problems. Most forms of cellular therapy use stem/progenitor cells or stem-like cells, which have the capacity to migrate, engraft and exert anti-inflammatory effects. Although some of these cell-based therapies have made their way to clinical trials in adults, little headway has been made in the neonatal patient group. This review discusses the efficacy of cell therapy in preclinical studies to date and their potential applications to diseases that afflict many prematurely born infants. Specifically, we identify the major hurdles that must be overcome before cell therapies can be safely used in the neonatal intensive care unit.

AB - The severely preterm infant receives a multitude of life-saving interventions, many of which carry risks of serious side effects. Cell therapy is an important and promising arm of regenerative medicine that may address a number of these problems. Most forms of cellular therapy use stem/progenitor cells or stem-like cells, which have the capacity to migrate, engraft and exert anti-inflammatory effects. Although some of these cell-based therapies have made their way to clinical trials in adults, little headway has been made in the neonatal patient group. This review discusses the efficacy of cell therapy in preclinical studies to date and their potential applications to diseases that afflict many prematurely born infants. Specifically, we identify the major hurdles that must be overcome before cell therapies can be safely used in the neonatal intensive care unit.

KW - bronchopulmonary dysplasia

KW - cell therapy

KW - human amnion epithelial cells

KW - mesenchymal stromal cells

KW - prematurity

UR - http://www.sciencedirect.com/science/article/pii/S1465324914006732

U2 - 10.1016/j.jcyt.2014.06.004

DO - 10.1016/j.jcyt.2014.06.004

M3 - Article

VL - 16

SP - 1614

EP - 1628

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 12

ER -